Renal Biomarkers Market Report 2026

Renal Biomarkers Market Overview

• Renal Biomarkers market size has reached to $1.37 billion in 2025 • Expected to grow to $2.04 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Rising Chronic Kidney Disease Incidence Fuels Renal Biomarkers Market Growth • Market Trend: Collaborations Drive Advanced Biomarker Discovery And Precision Diagnostics In Renal Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Renal Biomarkers Market?

Renal biomarker refers to proteins, lipids, genes, metabolites, proteomic patterns, or cells that are found on a urinalysis that is employed to determine the glomerular filtration rate of the kidney, a drop in which indicates kidney damage. The renal biomarkers are used to estimate the nature and severity of kidney injury. The main types of biomarkers in renal biomarkers are functional biomarker, upregulated protein, and other biomarker types. Functional biomarkers refer to the biomarker that allows the diagnosis of kidney injury in individuals with normal kidney function, also in Chronic Kidney Disease patients where the same injury would give rise to a significant decrease in functional biomarkers such as Cr. The different diagnostic techniques include enzyme-linked immunosorbent assay, particle-enhanced turbidimbiometric immunoassay (PETIA), colorimetric assay, and chemiluminescent enzyme immunoassay (CLIA), liquid chromatography-mass spectrometry (LS-MS). The applications include diagnosis and disease progression monitoring and research homecare and are used by hospitals, diagnostic laboratories, and other end users.

What Is The Renal Biomarkers Market Growth Forecast?

The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to $2.04 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for predictive renal diagnostics, expansion of biomarker-based clinical research, growing integration of AI in biomarker analysis, increasing focus on personalized nephrology care. Major trends in the forecast period include increasing adoption of novel kidney injury biomarkers, rising use of multi-biomarker panels in diagnostics, growing demand for early detection of kidney damage, expansion of non-invasive urine-based testing, enhanced focus on disease progression monitoring.

Global Renal Biomarkers Market Segmentation

1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types 2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS) 3) By Application: Diagnosis And Disease Progression Monitoring, Clinical Research 4) By End User: Hospitals, Diagnostic Laboratories, Other End Users Subsegments: 1) By Functional Biomarker: Creatinine, Urea, Cystatin C, Bicarbonate 2) By Up Regulated Protein: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18) 3) By Other Biomarker Types: Proximal Tubule Injury Biomarkers, Acute Kidney Injury Biomarkers, Chronic Kidney Disease Biomarkers

What Is The Driver Of The Renal Biomarkers Market?

The rising burden of chronic kidney disease (CKD) is expected to propel the growth of the renal biomarkers market going forward. CKD is a long-term condition characterized by the gradual decline of kidney function, reducing the body’s ability to filter waste products, maintain fluid balance, and regulate essential electrolytes. The increasing prevalence of CKD is primarily driven by aging populations, diabetes, hypertension, and hereditary risks, all of which contribute to higher rates of kidney-related complications and mortality. Renal biomarkers play a crucial role in clinical practice by enabling earlier diagnosis, monitoring disease progression, and supporting timely therapeutic intervention to prevent kidney failure. For instance, in December 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease accounted for 1.1% of Australia’s total disease burden, with age-adjusted measurements showing that males experienced 1.3 times the burden observed in females. Therefore, the rising burden of chronic kidney disease is driving the growth of the renal biomarkers industry.

Key Players In The Global Renal Biomarkers Market

Major companies operating in the renal biomarkers market are Abbott Laboratories, BioPorto Diagnostics A S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Sphingotec GmbH, Bio Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Alere Inc., Bio Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R And D Systems Inc., Roche Diagnostics International Ltd, Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

Global Renal Biomarkers Market Trends and Insights

Major companies operating in the renal biomarkers market are increasingly forming advanced collaborations with research organizations and AI-enabled biotechnology firms to enhance biomarker discovery, improve patient stratification, and strengthen precision diagnostic capabilities. These strategic partnerships aim to accelerate the identification and validation of novel biomarkers that support early disease detection, refined risk assessment, and personalized treatment approaches for kidney disorders. For instance, in November 2024, MultiOmic Health, a UK-based AI-powered drug discovery company, identified novel patient endotypes and proprietary biomarkers for diabetic kidney disease (DKD) through a research collaboration with the Northern Care Alliance NHS Foundation Trust. These biomarkers enable precise patient segmentation and facilitate the development of targeted diagnostic tools and therapeutics, supporting improved clinical decision-making and outcomes in kidney care.

What Are Latest Mergers And Acquisitions In The Renal Biomarkers Market?

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed amount. This rare acquisition of a Chinese biotech by a multinational highlights China's potential in the global renal market and aligns with Novartis' focus on innovative kidney disease therapies. SanReno Therapeutics is a China-based biopharma company that specializes in renal disease therapies.

Regional Outlook

North America was the largest region in the renal biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Renal Biomarkers Market?

The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Renal Biomarkers Market Report 2026?

The renal biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.